Cipla

Cipla, Stempeutics launch stem cell therapy for knee osteoarthritis

Approved by the Drug Controller General of India (DCGI), the treatment offers to slow disease progression and promote cartilage maintenance for patients with Grade II and III knee OA

Cipla launches India's first integrated lung diagnostics, wellness centre

The Delhi facility offers over 60 advanced tests and aims to close critical gaps in respiratory diagnosis and care

Torrent Pharma surpasses Cipla in mcap ranking; soars 6% on Nov 10

Torrent Pharma market capitalisation stood at ₹1.28 trillion on Monday, while that of Cipla at ₹1.22 trillion, shows BSE.

Stocks to Watch today, Nov 4: Bharti Airtel, Titan, Hero MotoCorp, Cipla

Stocks to Watch today, November 4, 2025: From Bharti Airtel, Hero MotoCorp, Titan Company, and Power Grid, here is a list of stocks that will be in focus today

Cipla Q2 revenue grows, margins squeeze; analysts decode stock strategy

In the Q2FY26, Cipla reported consolidated revenue from operations of ₹7,589 crore, up 8 per cent year-on-year (Y-o-Y) from ₹7,051 crore in the year-ago period

Achin Gupta to succeed Umang Vohra as Cipla MD & GCEO from April 2026

Umang Vohra joined Cipla in 2015 as global chief financial and strategy officer and thereafter served as the company's MD & GCEO since 2016

Cipla Q2 results: Profit rises 4%, revenue hits record ₹7,589 crore

The company bets on Eli Lilly tie-up for GLP-1 drug, biosimilars expansion; reaffirms $1 billion US revenue goal

Cipla's global CEO Umang Vohra to step down, COO Achin Gupta to take over

Umang Vohra was responsible for leading Cipla through a phase of strategic transformation, strengthening its global leadership in respiratory therapies, and digital and manufacturing capabilities

Cipla Q2FY26 results: Net profit rises 3.7% to ₹1,353 cr on higher revenue

Pharma major Cipla Ltd on Thursday reported a 3.7 per cent rise in consolidated net profit at Rs 1,353.37 crore for the second quarter ended September 30, 2025. The company had posted a consolidated net profit of Rs 1,305.01 crore in the second quarter of the last fiscal year, Cipla Ltd said in a regulatory filing. Consolidated total revenue from operations in the second quarter stood at Rs 7,589.44 crore, as against Rs 7,051.02 crore in the year-ago period, it added. Total expenses in the quarter under review were higher at Rs 6,004.86 crore, as compared to Rs 5,452.57 crore in the corresponding period last fiscal, the company said. In the second quarter, the pharmaceuticals segment clocked revenue of Rs 7,291.43 crore, as against Rs 6,775.56 crore in the same period a year ago. New ventures registered revenue of Rs 350.68 crore, as against Rs 319.6 crore, the filing said.

Cipla Q2 preview: Pharma major may see stable qtr; check key estimates here

Cipla is expected to report a profit after tax (PAT) of ₹1,361.6 crore for the September 2025 quarter, against ₹1,302.5 crore in Q2FY25

Nuvama retains 'Hold' on Cipla, raises target after Eli Lilly diabetes deal

Cipla- Eli Lilly deal: Tirzepatide is a prescription drug used for managing type 2 diabetes and aiding weight loss in adults who are obese or overweight.

Lilly and Cipla to market tirzepatide in India under new brand Yurpeak

The Lilly-Cipla collaboration brings a second brand of tirzepatide, Yurpeak, to India, aiming to widen patient access for diabetes and obesity care across urban and semi-urban markets

Cipla rallies 4%, hits 52-week high; Choice Broking sees more upside

Cipla stock outlook: A decisive breakout above ₹1,580 could trigger further upward momentum, paving the way towards the ₹1,770-₹1,850 target range in the medium term, said Choice Broking.

Lupin, Granules: Which pharma stocks to buy, sell amid US tariff flip-flop?

Technical charts show that select pharma stocks are trading with a negative bias and can tumble up to 19% from here. Granules India, however, looks strong on chart and can rally up to 19%.

Nifty Pharma down 2.5% as Trump slaps 100% import tariffs; impact decoded

Among individual counters, Sun Pharma slumped 4.87 per cent to a fresh 52-week low of ₹1,548, while Gland Pharma tumbled 4.70 per cent to ₹1,880. Biocon declined 3.68 per cent to ₹342.85.

Dr Reddy's, Sun: Pharma stocks can crash up to 30% on Trump's 100% tariff

Indian pharma shares - Dr.Reddy's, Cipla, Sun, Lupin and Aurobindo Pharma stare at up to 30 downside risk hint technical charts as US President Donald Trump announces 100% tariff on pharma imports.

Cipla launches Huena, India's first non-antibiotic drug to fight UTI

Drug firm Cipla on Friday said it has introduced a non-antibiotic treatment for patients suffering from recurrent urinary tract infections. The company has launched Methenamine Hippurate under the brand name HUENA. This marks a significant step forward for the company in its fight against anti-microbial resistance as it becomes the first to introduce such treatment in India, the Mumbai-based drugmaker said in a statement. Urinary tract infections (UTIs) are the second most common reason for antibiotic use in India, with infection cases doubling over the last 30 years. Women are more susceptible to UTIs, which account for 15 per cent of overall antibiotic prescriptions. Methenamine Hippurate offers an effective, non-antibiotic alternative for preventing UTIs by targeting bacteria in the bladder and urinary tract. Studies show it is as effective as long-term, low-dose antibiotic therapy for UTI prevention, with lower costs and no risk of antibiotic resistance. "We believe this ...

Looking for short-term F&O trade? Check this 'Bull Spread' on Cipla

Short term trend is positive as it is placed above its 5, 11 and 20 day EMA Stock price has broken out on the weekly chart with higher volumes

Next US fix could stanch Cipla's Revlimid bleed amid pricing pressure

Generics pipeline starts to pulse as Advair, Symbicort, and Abraxane prepare to hit the vein

Cipla Q1 net profit up 10%, driven by consumer health and generics

Cipla reports a 10% increase in Q1FY26 net profit, fueled by strong performance in the generics and consumer health segments